Baird lowered the firm’s price target on Enanta (ENTA) to $20 from $26 and keeps an Outperform rating on the shares. The firm said the Q4 report was straightforward, and noted they are on the precipice of the crucial RSVPEDs readout in December, which Baird thinks will be the key determinant of zelicapavir’s future potential in RSV.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio